Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023

BACKGROUND: Data on the contemporary prevalence of hypertrophic cardiomyopathy (HCM) in the United States are limited, and information on the epidemiology by disease characteristics and patient demographics is lacking. OBJECTIVES: This study aimed to estimate the prevalence and incidence of HCM in the United States from 2016 to 2023 overall and stratified by patient subgroups. METHODS: In this observational study, patient-level administrative claims from 2016 to 2023 were collected from the Symphony Integrated Dataverse. Selected patients were those with ≥1 HCM diagnosis code during the study period. Patients were designated as having nonobstructive HCM (nHCM), obstructive HCM (oHCM), and symptomatic HCM using diagnosis codes. RESULTS: During the period of 2016-2023, there were 431,457 HCM cases in the total population of 141,003,247 patients for a prevalence rate of 1/327 individuals (95% CI: 1/326-328). The incidence of HCM was 50/100,000 (95% CI: 50-51/100,000) in 2017 and was 56/100,000 (95% CI: 56-57/100,000) in 2023. The rates in nHCM and oHCM were 188/100,000 (95% CI: 187-189/100,000) and 117/100,000 (95% CI: 117-118/100,000), respectively. Similarly, the incidence in asymptomatic and symptomatic HCM was 171/100,000 (95% CI: 171-172/100,000) and 135/100,000 (95% CI: 134-135/100,000), respectively. Prevalence generally increased with age and was higher in males than in females (341/100,000 [95% CI: 339-342/100,000] vs 277/100,000 [95% CI: 275-278/100,000], respectively). The regions and locations of individual states with the highest HCM, oHCM, and nHCM rates were in the Northeast and Midwest. CONCLUSIONS: In this administrative claims-based study, the prevalence of HCM from 2016 to 2023 was 1/327 individuals, which translates to an estimated 832,956 HCM cases in the United States.